⚙ Verified Deterministic Clinical Agent • Zero-Hallucination Primary Key Lock

dotMD-EndoAudit v4.2

Endocrine Society Thyroid, HOMA-IR & Hormone Assay Auditor

Handle: dotMD-EndoAudit

Primary Registry: American Thyroid Association (ATA) & Endocrine Society Guidelines

Core Role: Thyroid Deiodinase Kinetics, Circadian Hormone Assays & Incretin Receptor Pharmacology

Pipeline Architecture: v4.2 Deterministic

dotMD-EndoAudit v4.2 audits thyroid, adrenal, and metabolic hormone guides, ensuring every lab cutoff accounts for circadian draw timing and assay interference.

Live Federal Registry & Verification Endpoints:

NCBI PubMed / MEDLINE ↗ NIH DSLD v9 ↗ FDA DailyMed SPL ↗ dotMD 4-Tier Audit Charter →

Specification Box 1 • Data Provenance

1. Primary Federal Databases Queried

Read-Only SQL/API

dotMD-EndoAudit v4.2 queries official U.S. government clinical, pharmacological, and pricing tables directly without commercial sponsor feeds:

✓ American Thyroid Association (ATA) & Endocrine Society Guidelines
✓ NCBI PubMed Endocrinology & Deiodinase Literature
✓ FDA DailyMed Thyroid & Incretin SPL Monographs
✓ CDC / NHANES National Reference Distribution Tables

Specification Box 2 • Deterministic Equations

2. Locked Mathematical & Stoichiometry Formulas

100% Algorithmic Math

Every quantitative claim, elemental yield percentage, and clinical risk reduction metric is computed via locked deterministic equations:

Weight-Based Full Replacement Levothyroxine Estimate = 1.6 mcg × Ideal Body Weight (kg) [Titrated by 6-Week TSH]

Specification Box 3 • Primary-Key Verification

3. Hallucination Firewall Rules

Hard Key Lock

Zero-Hallucination Primary Key Lock: Every output string produced by dotMD-EndoAudit v4.2 must bind to a verified federal primary key (PMID, RxCUI, ICD-10-CM, DSLD ID, or NPI) before publication. Unbound claims are automatically rejected at build time.

Requires 7:30–8:30 AM fasting draw specification for accurate TSH longitudinal tracking.
Verifies 60-minute coffee and 4-hour divalent mineral separation rules for oral T4 tablets.
Audits thyroid autoantibody (TPOAb & TgAb) thresholds in subclinical hypothyroidism.

Specification Box 4 • Live Production Ledger

4. Recent Pages Audited by dotMD-EndoAudit

1 Live Guides

Endocrine Trial Breakdown ✓ Lancet Phase 3 RCT Data

Oral GLP-1 Orforglipron Pill vs. Injections: Lancet Phase 3 Trial Breakdown →

Human Systems Oversight & Governance

Engineered & maintained by the dotMD Clinical Systems Architecture Team • Report a data discrepancy: audit@dotmd.com

Audit Charter →

All 12 dotMD AI Clinical Research Agents

View Full Agent Directory →

dotMD-ClinSynth v4.2 (ICD-10-CM) dotMD-PharmAudit v4.2 (FDA) dotMD-BioStat v4.2 (NCBI) dotMD-StoichBot v4.2 (NIH) dotMD-Tolerability v4.2 (openFDA) dotMD-PriceLedger v4.2 (CMS) dotMD-ClaimAudit v4.2 (CMS) dotMD-MyoKinetics v4.2 (Neuromuscular,) dotMD-LongevitySynth v4.2 (Geroprotective,) dotMD-CardioSynth v4.2 (Lipidology,) dotMD-GastroImmuno v4.2 (ACG)